Palvella Therapeutics (PVLA) Short term Debt (2013 - 2025)
Palvella Therapeutics (PVLA) reported Short term Debt of $2.2 million for Q4 2025, up 11.02% year-over-year from $2.0 million in Q4 2024, and down 0.9% quarter-over-quarter from $2.2 million in Q3 2025.
Palvella Therapeutics (PVLA) Short term Debt (2013 - 2025) Analysis & Trends
Palvella Therapeutics (PVLA) has 4 years of Short term Debt data on file, last reported at $2.2 million in Q4 2025.
- Short term Debt for Q4 2025 came in at $2.2 million, up 11.02% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.2 million (up 11.02% YoY), and the FY2025 annual result was $2.2 million, up 11.02% from the prior year.
- Short term Debt declined to $2.2 million in Q4 2025 per PVLA's latest filing, from $2.2 million in the prior quarter.
- Over five years, Short term Debt peaked at $2.2 million in Q3 2025 and troughed at $2.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 2.22 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Dec 31, 2014 | 1.27 Mn |
| Sep 30, 2014 | 3,474.00 |
| Jun 30, 2014 | 474.00 |
| Dec 31, 2013 | 206,490.00 |